AFJPS African Journal of Pharmaceutical Sciences 2789-5092 SvedbergOpen afjps-1-1-002 10.51483/AFJPS.1.1.2021.11-15 Short Communication Target Therapy, from its Initial Clinical Breakthroughs to Current Hot Spot ZhuGeorge 1 * 1Tehran University of Medical Sciences, Tehran, Iran. E-mail: sansan4240732@163.com *Corresponding author: George Zhu, Tehran University of Medical Sciences, Tehran, Iran. E-mail: sansan4240732@163.com 09 2021 1 1 11 15 Abstract

Epidermal growth factor (EGF) is a polypeptide hormone originally isolated from mouse submaxillary gland, which is a potent mitogen for a wide variety of culture cells of both epithelial and mesenchymal origin, and its important role in the proliferation, differentiation, and survival of neural and glial precursor cells. The physiological effects of EGF are mediated by an EGF receptor with tyrosine-specific protein kinase activity. The traditionally accepted view is that normal epidermal growth factor receptor (EGFR) is no tumorigenic, whereas mutated EGFR is oncogenic. Recently, it has been implicated that EGF could be beneficial for burn, wound healing, diabetic foot ulcer, and show an attractive perspective In addition, cosmetic containing EGF would be effective in improving the plasticity of skin, helps in anti-aging and whitening, and controls the amount of erythema and sebum in the skin. In our team we have successfully prepared a series of 206 bottles of Shampoo liquid and 20 bottles of recombinant human EGF (rhEGF) spray, and 4 bottles of EGF- Silvadence ointment. The initial results indicated that prepared rhEGF is safe and available in clinical use. On the other hand, progress on the interaction of EGF with its mutated oncogenic receptors in the development of some cancers such as A431 human SCC cells, brain glioblastoma, breast, pancreas and lung cancers. In addition to a series of gefitinib, erlotinib, osimertinib and the CIMAvax-EGF vaccine, an antioncogenic receptor antibodybased fusion protein [for example Cetuximab-based IL-10 fusion protein, CmAb-(IL10)2] provide a potential strategy to improve cancer immunotherapy.

 Keywords EGF EGFR and oncogenic receptor EGFR Target therapy References AfsbariM.LarijaniB.FadayeeM. et al. (2005). Efficacy of Topical Epidermal Growth Factor in Healing Diabetic Foot Ulcer. Therapy, 2(5), 759–765. Al-NedawiK.MeehanB.MicallefJ. et al. (2008). Intracellular Transfer of the Oncogenic Receptor EGFRvIII by Microvesicles Derived from Tumour Cells. Nat Cell Biol, 10, 619–624. BrownG., L., NanneyL.B.GroffenJ. et al. (1989). Enhancement of Wound Healing by Topical Treatment With Epidermal Growth Factor. N Engl J Med, 321, 76–79. ChiharaE.TakedaH.KuboT. et al. (2009). Chemo Preventive Effect of Gefitinib on Non-smoking-related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Res, 69, 7088–7095. CohenS. (1962). Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-born Animal. J Biol Chem, 237, 1555–1562. CrossD.A.AshtonS.E.GhiorghiuS. et al. (2014). AZD9291, An Irreversible EGFR TKI, Overcomes T790M-mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov, 4(9), 1046–61. FinlayM.R.AndertonM.AshtonS. et al. (2014). Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of both Sensitizing and T790M Resistance Mutations that Spares the Wild Type Form of the Receptor. J Med Chem, 57(20), 8249–67. GregoryH. (1975). Isolation and Structure of Urogastrone and its Relationship in Epidermal Growth Factor. Nature, 257, 325–327. GreulichH.ChenT.H.JanneP.A. et al. (2005). Oncogenic Transformation by Inhibitor-sensitive and -Resistant EGFR Mutants. PloSMed, 2(11), e313. KonduriK.GallantJ.N.ChaeY.K. et al. (2016). EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov, 6, 601–611. LynchT.J.BellD.W.SordellaR. et al. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-small-cell Lung Cancer to Gefitinib. N Engl J Med, 350(21), 2129–39. MokT.S.WuY.L.AhnM.J. et al. (2017). Osimertinib or Platinum-pemetrexed in EGFR T790M-positive Lung Cancer. N Engl J Med, 376, 629–640. MonterminiL.MeehanB.GarnierD. et al. (2015). Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Exttacellular Vesicle and Impacts Their Phosphoprotein and DNA Content. J Biol Chem, 290(40), 24534–24546. O’ConnorR. (2008). Concealed Cargo Within The Tumor Microenvironment: Microvesicles Disseminate Oncogenic Receptors Among Cancer Cells. Cancer Biol Ther, 7, 1350–51. QiaoJ.LiuZ.D.FuY.X. et al. (2019). Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell, 35, 901–915. RobinsonB. (2008). Tumor Cells Share Oncogenic Receptors. J Cell Biol, 181, 570. RodriguezP.C.PopaX.MartinezO. et al. (2016). A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMavax-EGF as Switch Maintenance Therapy in Advanced Non-small-cell Lung Cancer Patients. Clin Cancer Res, 22(15), 3782–3790. RodriguezP.C.RodrigueG.GonzalezG. et al. (2010). Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy. MEDICC Rev, 12(1), 17–23. StoscheckC.M.KingL.E. (1986). Role of Epidermal Growth Factor in Carcinogenesis. Cancer Res, 46(3), 1030–7. TangC.K.GangX.Q.WongA.J. et al. (2000). Epidermal Growth Factor Receptor vIII Enhances Tumorigenicity in Human Breast Cancer. Cancer Res, 60(11), 3081–3087. WangS.L.GuoZ.R.Fu X.B. et al. (1998). Effects of Recombinant Human Epidermal Growth Factor on Healing of Chronic Ulcer Wound. Chinese J Traumat (in chinese), 14(6), 348–349. WongW.K.R.NgK.L.HuX.H. et al. (2018). Authentic Human Epidermal Growth Factor: A Panacea for Wound Healing. ECEndocrMetab Res, 3(4), 138–146. YanT.MizutaniA.ChenL. et al. (2014). Characterization of Cancer Stem-like Cells Derived from Mouse Induced Pluripotent Stem Cells Transformed by Tumor-derived Extra-cellular Vesicle. J Cancer, 5(7), 572–584. ZhuG. (1992). Oncogenic Receptor Hypothesis (1989-91). VOA (Voice of America), 12, 31. ZhuG. (2018). Treatment of Patients with Advanced Cancer Following Chemotherapy and Traditional Medicine-Long Term Follow up of 75 Cases. Univ J Pharm Res, 3(3), 10–18. ZhuG. (2018). EpCAM-An Old Cancer Antigen,Turned Oncogenic Receptor and Its Targeting Immunotherapy. Univ J PharmRes, 3(2), 41–46. ZhuG. (2019). Vitamin A and its Derivatives-retinoic Acid and Retinoid Pharmacology. Am J Biomed Sci & Res, 3(2), 162–177. ZhuG.MischeS.E.SeigneresB. (2013). Novel Treatment of Acute Promyelocytic Leukemia: As2O3, Retinoic Acid and Retinoid Pharmacology. Curr Pharm Biotechnol, 14(14), 849–858. ZhuG.Saboor-YaraghiA.A.YardenY. et al. (2016). Downregulating Oncogenic Receptor: From Bench to Clinic. HematolMed Oncol, 1(1), 30–40. ZhuG.MusumecciF.ByrneP. et al. (2017). A Pilot Study of Lung Cancer Following Chemotherapy and Traditional Medicine: Report of 12 Cases. Lungs and Breath J, 1(3), 1–4. ZhuG.MusumeciF.ByrneP. (2013). Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Literature. Curr Pharm Biotechnol, 14(9), 859–863. ZhuG.XuH.L.ZhiQ.W. et al. (2020). Enhancement of Wound Healing by Topical Application of Epidermal Growth Factor in Animal Model. Univ J Pharm Res, 5(1), 12–20.